March 29, 2021 by Chain Drug Review
Lee Ann Stember president and chief executive officer at the National Council for Prescription Drug Programs, Pharmaceutical Care Management Association, Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott
Leading Headlines, Pharmacy
WASHINGTON — The number of independent pharmacies in the United States increased in 2020, according to a new analysis of pharmacy data. Pharmacy data from the National Council for Prescription Drug Programs, analyzed by the healthcare analytics firm Quest Analytics, shows the overall number of independent pharmacy stores increased by 449 between January 2020 and
September 30, 2020 by Chain Drug Review
JC Scott, PBMs, Pharmaceutical Care Management Association
Leading Headlines, Pharmacy
WASHINGTON — Pharmaceutical Care Management Association president and CEO JC Scott issued the following statement on today’s hearing in the House Committee on Oversight and Reform on pricing practices for prescription drugs: “We appreciate the House Oversight Committee keeping a spotlight on drug manufacturers’ pricing practices. While drug manufacturers are solely responsible for setting and
May 28, 2020 by Chain Drug Review
COVD-19, NACDS, Pharmaceutical Care Management Association, supply chain
Leading Headlines, Pharmacy
WASHINGTON — Representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; wholesalers; retail, specialty, and managed care, pharmacies; health insurance providers and other payers; pharmacists in hospitals and health systems; and pharmacy benefit managers, released on Thursday new policy principles to promote undisrupted patient access to medications
July 5, 2018 by Chain Drug Review
drug pricing, Mark Merritt, PCMA, Pharmaceutical Care Management Association
Leading Headlines, Pharmacy
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on reports of yet another round of massive price hikes by drug manufacturers. “News of recent price increases by drugmakers further confirms that the easiest way to lower costs would be for drug companies to lower their prices.” This
June 5, 2018 by Chain Drug Review
Mark Merritt, Pharmaceutical Care Management Association
Leading Headlines, Pharmacy
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) released the following statement on a Medicare Part D report released by the Office of Inspector (OIG), U.S. Department of Health and Human Services (HHS): “This report finally debunks the myth that drugmakers have somehow been compelled to raise prices because of the discounts and rebates health plans
May 8, 2018 by Chain Drug Review
American Diabetes Association, insulin prices, Pharmaceutical Care Management Association
Pharmacy
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) released the following statement regarding a white paper released today by the American Diabetes Association on insulin prices: “The American Diabetes Association’s new white paper on insulin prices confirms that drugmakers set, and continue to raise, prices. Along with high prices for insulin products, drug manufacturer product
May 7, 2018 by Chain Drug Review
Mark Merritt, PCMA, Pharmaceutical Care Management Association
Leading Headlines, Pharmacy
WASHINGTON — After 15 years of heading up the Pharmaceutical Care Management Association (PCMA), chief executive officer and president Mark Merritt is stepping down, effective at year-end. Under Merritt’s leadership, PCMA grew from an obscure group into the nation’s leading voice on prescription drug benefits. One of his first missions was to help shape the bill
April 4, 2018 by Bill Schiffner
Department of Health and Human Services, Mark Merritt, Medicare Part D, Pharmaceutical Care Management Association
Leading Headlines, Pharmacy
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on the Medicare Part D final rule released this week by the Department of Health and Human Services: “Two years ago drugmakers launched a campaign to deflect blame for their high prices onto health plans and pharmacy benefit
March 16, 2018 by Chain Drug Review
American Pharmacists Association, B. Douglas Hoey, Claire McCaskill, CVS Health, Debbie Stabenow, Know the Lowest Price Act, National Community Pharmacists Association, Patient Right to Know Drug Prices Act, Pharmaceutical Care Management Association, pharmacy gag clauses, prescription drug pricing transparency, S. 2553, S. 2554, Susan Collins, Tom Menighan
Featured Articles, Leading Headlines, Pharmacy, Retail News
WASHINGTON — A group of senators are sponsoring legislation to bring more prescription drug pricing transparency to the pharmacy counter. Sens. Susan Collins (R., Maine), Claire McCaskill (D., Mo.) and Debbie Stabenow (D., Mich.) yesterday introduced the Patient Right to Know Drug Prices Act (S. 2554) and the Know the Lowest Price Act (S. 2553), which would
February 12, 2018 by Geoff Walden and Chain Drug Review
B. Douglas Hoey, Centers for Medicare & Medicaid Services, DIR fees, direct and indirect remuneration fees, NACDS, National Association of Chain Drug Stores, National Community Pharmacists Association, NCPA, PCMA, Pharmaceutical Care Management Association, Steve Anderson
2018, Issue 02-12-2018, Issues, News
ARLINGTON, Va. — The “untenable” procedures around direct and indirect remuneration fees (DIR fees) can be righted with measures reducing costs for beneficiaries and the government, while promoting a more quality-driven health care system, says the National Association of Chain Drug Stores. NACDS expressed that message in comments to the Centers for Medicare & Medicaid
December 13, 2017 by Chain Drug Review
B. Douglas Hoey, DIR fees, Examining the Drug Supply Chain, Mark Merritt, National Community Pharmacists Association, NCPA, PBM industry, Pharmaceutical Care Management Association, pharmacy benefit manager, prescription drug costs, U.S. House of Representatives Energy & Commerce Committee, video
Videos
At a health subcommittee hearing of the U.S. House of Representatives Energy & Commerce Committee, B. Douglas Hoey, CEO of the National Community Pharmacists Association (NCPA), called for legislative and regulatory action on pharmacy benefit manager (PBM) business practices to help rein in prescription drug costs. The hearing, titled “Examining the Drug Supply Chain”
October 17, 2017 by Chain Drug Review
Cost of Prescription Drugs: How the Delivery System Affects What Patients Pay, DIR fees, H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, Mark Merritt, National Community Pharmacists Association, Pharmaceutical Care Management Association, pharmacy benefit managers, prescription drug costs, S. 413, Senate HELP Committee, Senior Care Pharmacy Coalition
Featured Articles, Leading Headlines, Pharmacy, Retail News
WASHINGTON — Pharmacy benefit managers are a key focus of debate about elevated drug pricing that has come before a U.S. Senate committee. The National Community Pharmacists Association (NCPA) and the Senior Care Pharmacy Coalition (SCPC) called for PBM reform in written testimony submitted to a Senate Health, Education, Labor and Pensions (HELP) Committee hearing
June 23, 2017 by Chain Drug Review
Act 900, Arkansas Pharmacists Association, B. Douglas Hoey, generic drug reimbursement, Mark Merritt, National Community Pharmacists Association, NCPA, PCMA, Pharmaceutical Care Management Association, prescription drug pricing
Leading Headlines, Pharmacy, Retail News
ALEXANDRIA, Va. — The National Community Pharmacists Association and the Arkansas Pharmacists Association (APA) have filed an amici curiae brief in federal court against a challenge by the Pharmaceutical Care Management Association (PCMA). NCPA said the brief, filed in the U.S. Court of Appeals for the Eighth Circuit, supports Arkansas in a lawsuit initiated by
April 25, 2017 by CDR Blog and Chain Drug Review
B. Douglas Hoey, DrugBenefitSolutions, independent community pharmacies, Mark Merritt, National Community Pharmacists Association, NCPA, NCPA's Congressional Pharmacy Fly-In, PBMs, PCMA, Pharmaceutical Care Management Association, pharmacy benefit managers, The PBM Story
CDR Blog
A lobbying event in Washington has triggered salvoes between two combatants: independent community pharmacies and pharmacy benefit managers. The National Community Pharmacists Association is holding its Congressional Pharmacy Fly-In advocacy drive this week, where it will also release “The PBM Story: What They Say, What They Do, and What Can Be Done About It,” offered